Nashua, N.H.-based DiagnosisOne's clinical decision support (CDS) system is being used to analyze cancer occurrences in Massachusetts to help physicians direct appropriate medical attention to patients, the company says.
The DiagnosisONE's CDS system was pilot-tested by Harvard Vanguard Medical Associates (HVMA) of Greater Boston to perform cancer surveillance based on claims data. This project, sponsored by Boston-based Blue Cross Blue Shield of Massachusetts (BCBSMA), uses the DiagnosisOne CDS engine to analyze drugs, tests and conditions based on anonymous claims data from patients.
DiagnosisOne develops and markets solutions to allow customers in the clinical and public health environments to collect data from disparate sources, apply clinical and bioterrorism rules to those data, and deliver the resulting information to care providers and decision-makers, it says.
